PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (" PolyPid ” or the " Company ”), a late-stage biopharma company aiming to improve surgical outcomes, today ...

The Montreal Protocol The Montreal Protocol on Substances that Deplete the Ozone Layer is the landmark multilateral environmental agreement that regulates the production and consumption of nearly 100 ...

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced ...

Akebia Therapeutics, Inc. announced the publication of pre-specified analyses from its global phase 3 clinical trials of vadadustat for treating anemia in chronic kidney disease (CKD) in the ...

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial.

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced drug can hold its own against FDA-approved products like Seysara and ...

Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (mOS) of between 8 and 11 months. With the use of modern chemotherapy ...

Background: PV is characterized by red blood cell overproduction. Rusfertide is a subcutaneous (SC), self-injected, first-in-class peptide hepcidin mimetic that decreases erythrocytosis. VERIFY ...

ARASTEP, a phase 3 randomized, double-blind, placebo-controlled study (NCT05794906) that is actively recruiting, is set to evaluate the use of darolutamide (Nubeqa) plus androgen deprivation therapy ...